ASX Filings
Read about Tryptamine Therapeutics Limited on the ASX
Previous Press Releases of Tryp
on the Canadian securities exchange
Read about Tryp Therapeutics on Sedar
All News
See below for a comprehensive list of news items published by Tryp Therapeutics.
Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital
Kelowna, Canada, (April 4, 2023) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused…
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
JANUARY 05, 2023 Interim data analysis supports the potential effectiveness of psilocybin-assisted psychotherapy for the treatment of Binge Eating Disorder Kelowna,…
Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
JANUARY 03, 2023 Kelowna, British Columbia, Canada — (January 3. 2023) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or…
Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023
DECEMBER 21, 2022 Company to be in San Francisco January 8-11, 2023, during 41st Annual J.P. Morgan Health Care Conference Kelowna, British…
Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights
DECEMBER 13, 2022 Kelowna, British Columbia, Canada – (December 13, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company…
Tryp Therapeutics to Webcast Live at VirtualInvestorConferences.com on Thursday, December 15
DECEMBER 12, 2022 ompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations…